As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib

BACKGROUND: Combination therapy of transarterial chemoembolization plus sorafenib (TACE-S) has been proven to be safe and effective for hepatocellular carcinoma (HCC); however, this combination therapy is associated with a high incidence of adverse events (AEs). Our study focused on the relationship...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lei, Wang, Enxin, Li, Lin, Chen, Dongyu, Peng, Kun, Wang, Mengmeng, Han, Guohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877904/
https://www.ncbi.nlm.nih.gov/pubmed/31815114
http://dx.doi.org/10.1155/2019/2576349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877904/
https://www.ncbi.nlm.nih.gov/pubmed/31815114
http://dx.doi.org/10.1155/2019/2576349

Ejemplares similares